These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22896808)

  • 1. ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
    Hopkins CR
    ACS Chem Neurosci; 2012 Aug; 3(8):632. PubMed ID: 22896808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezogabine (retigabine).
    Stafstrom CE; Grippon S; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Sep; 10(10):729-30. PubMed ID: 21959281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
    Splinter MY
    Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical discovery and development of ezogabine for the treatment of epilepsy.
    Jankovic S; Ilickovic I
    Expert Opin Drug Discov; 2013 Nov; 8(11):1429-37. PubMed ID: 24053653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezogabine (Potiga) toxicity.
    Med Lett Drugs Ther; 2013 Nov; 55(1430):96. PubMed ID: 24276503
    [No Abstract]   [Full Text] [Related]  

  • 9. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
    Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
    Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retigabine for partial onset seizures.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezogabine (Potiga) for epilepsy.
    Med Lett Drugs Ther; 2012 Aug; 54(1397):65-7. PubMed ID: 22907178
    [No Abstract]   [Full Text] [Related]  

  • 12. Ezogabine: development and role in the management of epileptic seizures.
    Verma A; Kumar R; Kumar M
    Mini Rev Med Chem; 2013 Apr; 13(5):697-705. PubMed ID: 22931529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket.
    Manville RW; Abbott GW
    Nat Commun; 2018 Sep; 9(1):3845. PubMed ID: 30242262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
    Faulkner MA; Burke RA
    Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures.
    Owen RT
    Drugs Today (Barc); 2010 Nov; 46(11):815-22. PubMed ID: 21225020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
    Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W
    Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
    Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
    Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine.
    Walleigh DJ; Legido A; Valencia I
    Pediatr Neurol; 2013 Nov; 49(5):368-9. PubMed ID: 23916860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
    Deeks ED
    CNS Drugs; 2011 Oct; 25(10):887-900. PubMed ID: 21936589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.